Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Ratio (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Equity Ratio for 15 consecutive years, with 0.94 as the latest value for Q1 2026.

  • For Q1 2026, Equity Ratio fell 0.72% year-over-year to 0.94; the TTM value through Mar 2026 reached 0.94, down 0.72%, while the annual FY2025 figure was 0.92, 0.73% down from the prior year.
  • Equity Ratio hit 0.94 in Q1 2026 for Agios Pharmaceuticals, up from 0.92 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.94 in Q1 2025 and bottomed at 0.85 in Q2 2024.
  • Average Equity Ratio over 5 years is 0.9, with a median of 0.9 recorded in 2023.
  • Year-over-year, Equity Ratio dropped 3.84% in 2024 and then increased 8.95% in 2025.
  • Agios Pharmaceuticals' Equity Ratio stood at 0.89 in 2022, then dropped by 2.61% to 0.87 in 2023, then grew by 7.06% to 0.93 in 2024, then fell by 0.73% to 0.92 in 2025, then increased by 1.76% to 0.94 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.94, 0.92, and 0.93 for Q1 2026, Q4 2025, and Q3 2025 respectively.